TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21704237
Drug: Extended-release tramadol/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tramadol/acetaminophen (tramadol 75 mg/acetaminophen 650 mg)
Study: 21704237
Drug: Immediate-release tramadol/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tramadol/acetaminophen (tramadol 37.5 mg/acetaminophen 325 mg)
Study: 16384765
Drug: Bexarotene gel
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene gel 1% with narrowband UVB phototherapy
Study: 16384765
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel with narrowband UVB phototherapy
Study: 12771113
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate)
Study: 10852275
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg i.v. pulse of methylprednisolone followed by 0.7 mg/kg/day oral prednisone (Group 1)
Study: 10852275
Drug: 0.7 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg/day prednisone without an i.v. pulse (Group 2, controls)
Study: 10852275
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg i.v. pulse of methylprednisolone followed by 0.5 mg/kg/day prednisone (Group 3)
Study: 9089425
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 (HTF) 25 mg
Study: 9089425
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 (HTF) 50 mg
Study: 9089425
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 (HTF) 100 mg
Study: 3643648
Drug: Oral course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral course of pivampicillin/pivmecillinam (PAPM)
Study: 3643648
Drug: Parenteral cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cefotaxime (CFT)
Study: 24169120
Drug: DermaVir (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DermaVir (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13; 0.8 mg at weeks 0, 1, 6, 7, 12, and 13)
Study: 24169120
Drug: DermaVir (intermediate-dose)
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: DermaVir (intermediate-dose)
Study: 22023876
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone tablets
Study: 19916848
Drug: Quetiapine (58.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (58.3 mg/day)
Study: 17030114
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium skim milk without added phylloquinone (1000 mg/d of extra calcium)
Study: 9408414
Drug: Minilaparotomy (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minilaparotomy (ML)
Study: 9408414
Drug: Minilaparotomy (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minilaparotomy (ML) and Conventional Approach (CA)
Study: 8431122
Drug: Desmopressin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin plus warfarin therapy
Study: 9773802
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (24 mg) plus dexamethasone (12 mg)
Study: 9773802
Drug: i.v. ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ondansetron (8 mg) plus dexamethasone (20 mg)
Study: 7824325
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous dose of vancomycin over 90 min upon anesthesia (Group 1)
Study: 7824325
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous dose of vancomycin followed by a second 7.5 mg/kg intravenous dose over 30 min (Group 2)
Study: 27682331
Drug: PSALTI intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSALTI intervention (physiotherapy and speech and language therapy) consisting of education, laryngeal hygiene and hydration, cough suppression techniques, breathing exercises and psychoeducational counselling.
Study: 27682331
Drug: PSALTI intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSALTI intervention (physiotherapy and speech and language therapy).
Study: 24069469
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole (400 mg) treatment followed by health hygiene education intervention.
Study: 16443788
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during adenosine-induced hyperemia
Study: 14735177
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus cisplatin (PC) - Paclitaxel 66 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Study: 14735177
Drug: Vinorelbine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine plus cisplatin (VC) - Vinorelbine 23 mg/m² i.v. on days 1, 8, and 15; Cisplatin 60 mg/m² i.v. on day 15.
Study: 9441769
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake (clear liquid diet on postoperative day 1, regular diet after tolerating 500 cc)
Study: 9441769
Drug: Traditional dietary
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dietary advancement (oral intake initiated after bowel function is documented)
Study: 3281603
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CyA) at an initial dosage of 5 mg/kg daily
Study: 23608654
Drug: Riboflavin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (1.6 mg/d) for 16 weeks
Study: 21691817
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Vitamin D2 supplementation (HDD) 50,000 IU capsules weekly for 8 weeks then monthly for 4 months (Stratum A)
Study: 21691817
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Vitamin D2 supplementation (HDD) for 16 weeks and then monthly for 2 months (Stratum B)
Study: 21691817
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Vitamin D2 supplementation (HDD)
Study: 22813231
Drug: Stimulation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation therapy
Study: 2570582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ridazolol and Molsidomine
Study: 29325336
Drug: Ropivacaine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (all doses)
Study: 25307476
Drug: skintrek cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: skintrek cream PUVA
Study: 16816861
Drug: PEG-INF alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-INF alpha-2a (180 microg or 135 microg/week) and RBV 900 mg/d
Study: 16816861
Drug: IFNalpha-2a (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha-2a (5 MIU/qod) and RBV 900 mg/d
Study: 11145354
Drug: Single-bottle bonding
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-bottle bonding agents
Study: 8885118
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg gentamicin loading dose
Study: 8885118
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg gentamicin standard dose
Study: 8885118
Drug: Two SGC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two SGC after the first dose
Study: 29967332
Drug: 0.5 ug/kg dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ug/kg dexmedetomidine + 100 μg sufentanil + 300 μg dexmedetomidine (study group)
Study: 29967332
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline + 100 μg sufentanil (control group)
Study: 24113055
Drug: 3-Dimensional Conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Study: 7948436
Drug: High-dose surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose surfactant treatment (200 mg/kg)
Study: 7948436
Drug: Low-dose surfactant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose surfactant treatment (100 mg/kg)
Study: 29277607
Drug: Mastic oleoresin
Normalized name: Capsicum Oleoresin
DrugBank: Capsicum oleoresin (DB11131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastic oleoresin (MO), 15g administered for three days through smoking the episiotomy wound
Study: 29277607
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MO treatment)
Study: 21738098
Drug: Pain clinic
Normalized name: Stopain Clinical
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain clinic (PC) evaluation with or without treatment
Study: 18458035
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo cream) with nitrous oxide/oxygen
Study: 8564129
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase aerosol, twice a day for six consecutive days
Study: 2021379
Drug: Multi-component behavioral
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component behavioral treatment package (IBD education, progressive muscle relaxation, thermal biofeedback, cognitive coping strategies)
Study: 2021379
Drug: Multi-component behavioral
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component behavioral treatment package
Study: 29679478
Drug: bleselumab (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleselumab (0.1, 0.3, 1.0 or 3.0 mg/kg)
Study: 29679478
Drug: bleselumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleselumab (1.0 or 3.0 mg/kg)
Study: 28662313
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) with concurrent cisplatin followed by adjuvant cisplatin plus fluorouracil
Study: 26197975
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) ingestion (150 mg/kg)
Study: 26197975
Drug: Glutamate (Glu)
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate (Glu) injection (0.5 M, 0.2 ml)
Study: 26197975
Drug: NaCl (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (placebo) injection (0.9%, 0.2 ml)
Study: 26197975
Drug: Pre-injection MSG
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-injection MSG ingestion
Study: 26197975
Drug: Glu injections
Normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glu injections into the masseter muscle
Study: 26197975
Drug: MSG ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSG ingestion and Glu injection in the jaw muscles
Study: 21921953
Drug: Ologen (OLO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ologen (OLO) implant
Study: 21921953
Drug: Low-dosage mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage mitomycin-C (MMC)
Study: 1988521
Drug: 6-monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly dosing
Study: 1988521
Drug: Yearly dosing
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yearly dosing (12 and 24 months after initial therapy)
Study: 6346588
Drug: Intradermal jet
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal jet injector
Study: 6346588
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection (half a million units)
Study: 3566845
Drug: Lisuride (Dopergin)
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (Dopergin) - average dosage 1 mg/d
Study: 3566845
Drug: Bromocriptine -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine - average dosage 10 mg/d
Study: 27577069
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus sunitinib (n=24)
Study: 27577069
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (n=25)
Study: 25008857
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Mg/d (oral magnesium supplementation)
Study: 20398561
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d for 8 weeks
Study: 10695183
Drug: Fixed Dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination (FDC) of rifampicin (RIF) and isoniazid (INH)
Study: 10695183
Drug: Separate formulation
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulation of rifampicin (RIF)
Study: 10695183
Drug: Imported FDC
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported FDC formulation of rifampicin (RIF) and isoniazid (INH)
Study: 6849741
Drug: Indoramin 50
Normalized name: indoramin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 50 mg
Study: 1685666
Drug: Disopyramide 150
Normalized name: disopyramide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 150 mg
Study: 6759334
Drug: Cefroxadine 1
Normalized name: cefroxadine
DrugBank: Cefroxadine (DB11367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefroxadine 1 g t.i.d. for five days
Study: 6759334
Drug: Cephalexin 1
Normalized name: cephalexin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1 g t.i.d. for five days
Study: 30596666
Drug: Cotrimoxazole 960
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole 960 mg/tablet (CTX group)
Study: 30596666
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo (PLC group)
Study: 21691746
Drug: Bosutinib 200-600
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200-600 mg with food
Study: 21691746
Drug: Bosutinib 200
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200 mg with food
Study: 21691746
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg with food
Study: 21691746
Drug: Bosutinib 200-800
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200-800 mg with food
Study: 21691746
Drug: Bosutinib 200-800
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200-800 mg
Study: 17572803
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (40 mg once weekly)
Study: 17572803
Drug: Iron bis-glycinate
Normalized name: prenatal vitamin no.86/iron bis-glycinate/folic acid 32 mg-1,000 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron bis-glycinate chelate-enriched cookies (3.8 mg, 3x/week for 8 weeks)
Study: 17572803
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions for children with depleted iron stores (< 15 ng/mL)
Study: 9263281
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g/d, divided in 3 doses of 10 g each) for 8 consecutive days during each interval between chemotherapy
Study: 8214727
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (75-micrograms bolus and infusion of 2.5 micrograms/mL at 15 mL/h)
Study: 8214727
Drug: Ultra low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultra low-dose bupivacaine (0.04%), epinephrine (1.7 micrograms/mL), and fentanyl (1.7 micrograms/mL) (15-mL bolus followed by infusion at 15 mL/h)
Study: 2962088
Drug: Human hemi-synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human hemi-synthetic insulin
Study: 2962088
Drug: Porcine MC-insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine MC-insulin
Study: 31328671
Drug: Robot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot therapy (RT) for 60 minutes
Study: 25770784
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for relatives of people with mental health problems
Study: 16524789
Drug: Original omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Original omeprazole (10 mg once daily after breakfast)
Study: 16524789
Drug: Omeprazole-Towa (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole-Towa (10 mg once daily after breakfast)
Study: 16524789
Drug: Omerap (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omerap (10 mg once daily after breakfast)
Study: 16524789
Drug: Omeprazon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazon (10 mg once daily after breakfast)
Study: 16524789
Drug: Ovulanze (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulanze (10 mg once daily after breakfast)
Study: 9499939
Drug: Road traffic
Normalized name: Road to Wellness KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Road traffic noise of 75 dBA for 15 min with 0.25 mg of alprazolam (Xanax®) ingested 1 hr before
Study: 9499939
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of alprazolam (Xanax®) without noise exposure
Study: 2831701
Drug: Delta-9-THC (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta-9-THC (doses of 2.5-15 mg)
Study: 27933161
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) and leukotriene-receptor antagonist (LTRA)
Study: 18622483
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine solution
Study: 10704956
Drug: Intravenous glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glycine (100 mg/kg or 200 mg/kg)
Study: 10704956
Drug: Oral D-cycloserine
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-cycloserine (50 mg)
Study: 10704956
Drug: Intravenous glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous glycine
Study: 10704956
Drug: Oral D-cycloserine
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-cycloserine
Study: 8167297
Drug: Large-scale therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-scale therapeutic trials of agents intended to alter outcome
Study: 4616803
Drug: Flavoxate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoxate (600 mg daily)
Study: 15526107
Drug: Carteolol 20
Normalized name: carteolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 20 mg/day for 7 days
Study: 15526107
Drug: Carteolol (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol (20, 40 or 80 mg p.o.)
Study: 15526107
Drug: Bisoprolol (beta(1)-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (beta(1)-adrenoceptor blocker)
Study: 7720769
Drug: 3% dorzolamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% dorzolamide, approximately 7.7 micrograms per day (21.3 mumol) dorzolamide hydrochloride, administered bilaterally q.i.d. for 14 days
Study: 7720769
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered bilaterally q.i.d. for 14 days
Study: 7720769
Drug: Acetazolamide, 125
Normalized name: AcetaZOLAMIDE, 125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 125 mg q.i.d.
Study: 1904333
Drug: Pravastatin 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 5, 10, 20, 40 mg
Study: 6118074
Drug: ORG NC45
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG NC45 0.1 mg/kg
Study: 6118074
Drug: ORG NC45
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG NC45 0.15 mg/kg
Study: 23788751
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/day plus erlotinib 150 mg/day
Study: 23788751
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day (placebo plus erlotinib)
Study: 19668882
Drug: Diphereline 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphereline 3.75 mg, 4 times every 28 days (group I)
Study: 19668882
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg, once a week for 6 weeks (group II)
Study: 15514287
Drug: Lithium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium dose of 250 micromol Li
Study: 15514287
Drug: Lithium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium dose of 213 micromol Li
Study: 15514287
Drug: Lithium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium dose of 175 micromol Li
Study: 15514287
Drug: Measuring serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measuring serum Li 3-9 h after the last dose
Study: 11176734
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg twice daily for 5 days)